Abstract
Summary
A method for diagnosing gastrointestinal Stromal Tumor
LPI (LP Information)' newest research report, the “Gastrointestinal Stromal Tumor Molecular Diagnostics Industry Forecast” looks at past sales and reviews total world Gastrointestinal Stromal Tumor Molecular Diagnostics sales in 2022, providing a comprehensive analysis by region and market sector of projected Gastrointestinal Stromal Tumor Molecular Diagnostics sales for 2023 through 2029. With Gastrointestinal Stromal Tumor Molecular Diagnostics sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Gastrointestinal Stromal Tumor Molecular Diagnostics industry.
This Insight Report provides a comprehensive analysis of the global Gastrointestinal Stromal Tumor Molecular Diagnostics landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Gastrointestinal Stromal Tumor Molecular Diagnostics portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Gastrointestinal Stromal Tumor Molecular Diagnostics market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Gastrointestinal Stromal Tumor Molecular Diagnostics and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Gastrointestinal Stromal Tumor Molecular Diagnostics.
The global Gastrointestinal Stromal Tumor Molecular Diagnostics market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.
United States market for Gastrointestinal Stromal Tumor Molecular Diagnostics is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for Gastrointestinal Stromal Tumor Molecular Diagnostics is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for Gastrointestinal Stromal Tumor Molecular Diagnostics is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key Gastrointestinal Stromal Tumor Molecular Diagnostics players cover Yin Feng Gene, KingMed, Geneis, Haplox, AmoyDX, Admera and GeneChem, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
This report presents a comprehensive overview, market shares, and growth opportunities of Gastrointestinal Stromal Tumor Molecular Diagnostics market by product type, application, key players and key regions and countries.
Market Segmentation:
Segmentation by type
PCR
FISH
DNA Sequencing
Gene Chip
Segmentation by application
Clinical Diagnosis
Drug Screening
Research
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Yin Feng Gene
KingMed
Geneis
Haplox
AmoyDX
Admera
GeneChem
LPI (LP Information)' newest research report, the “Gastrointestinal Stromal Tumor Molecular Diagnostics Industry Forecast” looks at past sales and reviews total world Gastrointestinal Stromal Tumor Molecular Diagnostics sales in 2022, providing a comprehensive analysis by region and market sector of projected Gastrointestinal Stromal Tumor Molecular Diagnostics sales for 2023 through 2029. With Gastrointestinal Stromal Tumor Molecular Diagnostics sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Gastrointestinal Stromal Tumor Molecular Diagnostics industry.
This Insight Report provides a comprehensive analysis of the global Gastrointestinal Stromal Tumor Molecular Diagnostics landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Gastrointestinal Stromal Tumor Molecular Diagnostics portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Gastrointestinal Stromal Tumor Molecular Diagnostics market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Gastrointestinal Stromal Tumor Molecular Diagnostics and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Gastrointestinal Stromal Tumor Molecular Diagnostics.
The global Gastrointestinal Stromal Tumor Molecular Diagnostics market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.
United States market for Gastrointestinal Stromal Tumor Molecular Diagnostics is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for Gastrointestinal Stromal Tumor Molecular Diagnostics is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for Gastrointestinal Stromal Tumor Molecular Diagnostics is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key Gastrointestinal Stromal Tumor Molecular Diagnostics players cover Yin Feng Gene, KingMed, Geneis, Haplox, AmoyDX, Admera and GeneChem, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
This report presents a comprehensive overview, market shares, and growth opportunities of Gastrointestinal Stromal Tumor Molecular Diagnostics market by product type, application, key players and key regions and countries.
Market Segmentation:
Segmentation by type
PCR
FISH
DNA Sequencing
Gene Chip
Segmentation by application
Clinical Diagnosis
Drug Screening
Research
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Yin Feng Gene
KingMed
Geneis
Haplox
AmoyDX
Admera
GeneChem
Table of Contents
1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Gastrointestinal Stromal Tumor Molecular Diagnostics Market Size 2018-2029
2.1.2 Gastrointestinal Stromal Tumor Molecular Diagnostics Market Size CAGR by Region 2018 VS 2022 VS 2029
2.2 Gastrointestinal Stromal Tumor Molecular Diagnostics Segment by Type
2.2.1 PCR
2.2.2 FISH
2.2.3 DNA Sequencing
2.2.4 Gene Chip
2.3 Gastrointestinal Stromal Tumor Molecular Diagnostics Market Size by Type
2.3.1 Gastrointestinal Stromal Tumor Molecular Diagnostics Market Size CAGR by Type (2018 VS 2022 VS 2029)
2.3.2 Global Gastrointestinal Stromal Tumor Molecular Diagnostics Market Size Market Share by Type (2018-2023)
2.4 Gastrointestinal Stromal Tumor Molecular Diagnostics Segment by Application
2.4.1 Clinical Diagnosis
2.4.2 Drug Screening
2.4.3 Research
2.5 Gastrointestinal Stromal Tumor Molecular Diagnostics Market Size by Application
2.5.1 Gastrointestinal Stromal Tumor Molecular Diagnostics Market Size CAGR by Application (2018 VS 2022 VS 2029)
2.5.2 Global Gastrointestinal Stromal Tumor Molecular Diagnostics Market Size Market Share by Application (2018-2023)
3 Gastrointestinal Stromal Tumor Molecular Diagnostics Market Size by Player
3.1 Gastrointestinal Stromal Tumor Molecular Diagnostics Market Size Market Share by Players
3.1.1 Global Gastrointestinal Stromal Tumor Molecular Diagnostics Revenue by Players (2018-2023)
3.1.2 Global Gastrointestinal Stromal Tumor Molecular Diagnostics Revenue Market Share by Players (2018-2023)
3.2 Global Gastrointestinal Stromal Tumor Molecular Diagnostics Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2021-2023)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 Gastrointestinal Stromal Tumor Molecular Diagnostics by Regions
4.1 Gastrointestinal Stromal Tumor Molecular Diagnostics Market Size by Regions (2018-2023)
4.2 Americas Gastrointestinal Stromal Tumor Molecular Diagnostics Market Size Growth (2018-2023)
4.3 APAC Gastrointestinal Stromal Tumor Molecular Diagnostics Market Size Growth (2018-2023)
4.4 Europe Gastrointestinal Stromal Tumor Molecular Diagnostics Market Size Growth (2018-2023)
4.5 Middle East & Africa Gastrointestinal Stromal Tumor Molecular Diagnostics Market Size Growth (2018-2023)
5 Americas
5.1 Americas Gastrointestinal Stromal Tumor Molecular Diagnostics Market Size by Country (2018-2023)
5.2 Americas Gastrointestinal Stromal Tumor Molecular Diagnostics Market Size by Type (2018-2023)
5.3 Americas Gastrointestinal Stromal Tumor Molecular Diagnostics Market Size by Application (2018-2023)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Gastrointestinal Stromal Tumor Molecular Diagnostics Market Size by Region (2018-2023)
6.2 APAC Gastrointestinal Stromal Tumor Molecular Diagnostics Market Size by Type (2018-2023)
6.3 APAC Gastrointestinal Stromal Tumor Molecular Diagnostics Market Size by Application (2018-2023)
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 Europe
7.1 Europe Gastrointestinal Stromal Tumor Molecular Diagnostics by Country (2018-2023)
7.2 Europe Gastrointestinal Stromal Tumor Molecular Diagnostics Market Size by Type (2018-2023)
7.3 Europe Gastrointestinal Stromal Tumor Molecular Diagnostics Market Size by Application (2018-2023)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Gastrointestinal Stromal Tumor Molecular Diagnostics by Region (2018-2023)
8.2 Middle East & Africa Gastrointestinal Stromal Tumor Molecular Diagnostics Market Size by Type (2018-2023)
8.3 Middle East & Africa Gastrointestinal Stromal Tumor Molecular Diagnostics Market Size by Application (2018-2023)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Global Gastrointestinal Stromal Tumor Molecular Diagnostics Market Forecast
10.1 Global Gastrointestinal Stromal Tumor Molecular Diagnostics Forecast by Regions (2024-2029)
10.1.1 Global Gastrointestinal Stromal Tumor Molecular Diagnostics Forecast by Regions (2024-2029)
10.1.2 Americas Gastrointestinal Stromal Tumor Molecular Diagnostics Forecast
10.1.3 APAC Gastrointestinal Stromal Tumor Molecular Diagnostics Forecast
10.1.4 Europe Gastrointestinal Stromal Tumor Molecular Diagnostics Forecast
10.1.5 Middle East & Africa Gastrointestinal Stromal Tumor Molecular Diagnostics Forecast
10.2 Americas Gastrointestinal Stromal Tumor Molecular Diagnostics Forecast by Country (2024-2029)
10.2.1 United States Gastrointestinal Stromal Tumor Molecular Diagnostics Market Forecast
10.2.2 Canada Gastrointestinal Stromal Tumor Molecular Diagnostics Market Forecast
10.2.3 Mexico Gastrointestinal Stromal Tumor Molecular Diagnostics Market Forecast
10.2.4 Brazil Gastrointestinal Stromal Tumor Molecular Diagnostics Market Forecast
10.3 APAC Gastrointestinal Stromal Tumor Molecular Diagnostics Forecast by Region (2024-2029)
10.3.1 China Gastrointestinal Stromal Tumor Molecular Diagnostics Market Forecast
10.3.2 Japan Gastrointestinal Stromal Tumor Molecular Diagnostics Market Forecast
10.3.3 Korea Gastrointestinal Stromal Tumor Molecular Diagnostics Market Forecast
10.3.4 Southeast Asia Gastrointestinal Stromal Tumor Molecular Diagnostics Market Forecast
10.3.5 India Gastrointestinal Stromal Tumor Molecular Diagnostics Market Forecast
10.3.6 Australia Gastrointestinal Stromal Tumor Molecular Diagnostics Market Forecast
10.4 Europe Gastrointestinal Stromal Tumor Molecular Diagnostics Forecast by Country (2024-2029)
10.4.1 Germany Gastrointestinal Stromal Tumor Molecular Diagnostics Market Forecast
10.4.2 France Gastrointestinal Stromal Tumor Molecular Diagnostics Market Forecast
10.4.3 UK Gastrointestinal Stromal Tumor Molecular Diagnostics Market Forecast
10.4.4 Italy Gastrointestinal Stromal Tumor Molecular Diagnostics Market Forecast
10.4.5 Russia Gastrointestinal Stromal Tumor Molecular Diagnostics Market Forecast
10.5 Middle East & Africa Gastrointestinal Stromal Tumor Molecular Diagnostics Forecast by Region (2024-2029)
10.5.1 Egypt Gastrointestinal Stromal Tumor Molecular Diagnostics Market Forecast
10.5.2 South Africa Gastrointestinal Stromal Tumor Molecular Diagnostics Market Forecast
10.5.3 Israel Gastrointestinal Stromal Tumor Molecular Diagnostics Market Forecast
10.5.4 Turkey Gastrointestinal Stromal Tumor Molecular Diagnostics Market Forecast
10.5.5 GCC Countries Gastrointestinal Stromal Tumor Molecular Diagnostics Market Forecast
10.6 Global Gastrointestinal Stromal Tumor Molecular Diagnostics Forecast by Type (2024-2029)
10.7 Global Gastrointestinal Stromal Tumor Molecular Diagnostics Forecast by Application (2024-2029)
11 Key Players Analysis
11.1 Yin Feng Gene
11.1.1 Yin Feng Gene Company Information
11.1.2 Yin Feng Gene Gastrointestinal Stromal Tumor Molecular Diagnostics Product Offered
11.1.3 Yin Feng Gene Gastrointestinal Stromal Tumor Molecular Diagnostics Revenue, Gross Margin and Market Share (2018-2023)
11.1.4 Yin Feng Gene Main Business Overview
11.1.5 Yin Feng Gene Latest Developments
11.2 KingMed
11.2.1 KingMed Company Information
11.2.2 KingMed Gastrointestinal Stromal Tumor Molecular Diagnostics Product Offered
11.2.3 KingMed Gastrointestinal Stromal Tumor Molecular Diagnostics Revenue, Gross Margin and Market Share (2018-2023)
11.2.4 KingMed Main Business Overview
11.2.5 KingMed Latest Developments
11.3 Geneis
11.3.1 Geneis Company Information
11.3.2 Geneis Gastrointestinal Stromal Tumor Molecular Diagnostics Product Offered
11.3.3 Geneis Gastrointestinal Stromal Tumor Molecular Diagnostics Revenue, Gross Margin and Market Share (2018-2023)
11.3.4 Geneis Main Business Overview
11.3.5 Geneis Latest Developments
11.4 Haplox
11.4.1 Haplox Company Information
11.4.2 Haplox Gastrointestinal Stromal Tumor Molecular Diagnostics Product Offered
11.4.3 Haplox Gastrointestinal Stromal Tumor Molecular Diagnostics Revenue, Gross Margin and Market Share (2018-2023)
11.4.4 Haplox Main Business Overview
11.4.5 Haplox Latest Developments
11.5 AmoyDX
11.5.1 AmoyDX Company Information
11.5.2 AmoyDX Gastrointestinal Stromal Tumor Molecular Diagnostics Product Offered
11.5.3 AmoyDX Gastrointestinal Stromal Tumor Molecular Diagnostics Revenue, Gross Margin and Market Share (2018-2023)
11.5.4 AmoyDX Main Business Overview
11.5.5 AmoyDX Latest Developments
11.6 Admera
11.6.1 Admera Company Information
11.6.2 Admera Gastrointestinal Stromal Tumor Molecular Diagnostics Product Offered
11.6.3 Admera Gastrointestinal Stromal Tumor Molecular Diagnostics Revenue, Gross Margin and Market Share (2018-2023)
11.6.4 Admera Main Business Overview
11.6.5 Admera Latest Developments
11.7 GeneChem
11.7.1 GeneChem Company Information
11.7.2 GeneChem Gastrointestinal Stromal Tumor Molecular Diagnostics Product Offered
11.7.3 GeneChem Gastrointestinal Stromal Tumor Molecular Diagnostics Revenue, Gross Margin and Market Share (2018-2023)
11.7.4 GeneChem Main Business Overview
11.7.5 GeneChem Latest Developments
12 Research Findings and Conclusion